The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability

Atherosclerosis. 1999 Nov 1;147(1):105-13. doi: 10.1016/s0021-9150(99)00177-x.

Abstract

The changes in low density lipoprotein (LDL) composition and oxidizability after LDL-apheresis (LA) using dextran sulfate cellulose columns were evaluated in 12 hypercholesterolemic men (mean+/-S.D. total cholesterol (TC) 9.7+/-1.8 mmol/l). After 10-20 months on biweekly LA combined with simvastatin 40 mg per day immediate pre-apheresis levels of TC, LDL-cholesterol, and apolipoprotein B were decreased to 5.3+/-1.3 mmol/l, 3.3+/-1.2 mmol/l, and 1.6+/-0.4 g/l, respectively, whereas apheresis induced mean acute reductions of 61, 78, and 76%, respectively. Measurements of copper-induced LDL-oxidizability in vitro showed an increased resistance against oxidation after LA until day 3 post-treatment: lag time (min) (day 0 (before LA) versus day 1 (post-LA)) 112+/-27 versus 130+/-26 (P=0.001), maximal rate of diene production (nmol/min per mg LDL) 11.1+/-2.7 versus 9.1+/-2.1 (P=0.001), and time to maximal diene production (min) 186+/-39 versus 209+/-35 (P=0. 001). Analysis of the chemical composition of LDL revealed a 25% (P<0.001) reduced content of cholesteryl esters and a decrease of the cholesterol to protein ratio of 1.20+/-0.25 to 0.70+/-0.22 (P<0. 001) through the 3rd day post-LA. Linoleic acid and arachidonic acid content of LDL decreased 11 and 18%, respectively, at the expense of palmitic acid. Vitamin E levels (mg/l) were significantly lowered due to reduction of the lipoprotein pool by apheresis; however, vitamin E content of LDL did not change in the days after apheresis when expressed per g protein or per micromol linoleic acid. The changes in fatty acid pattern were strongly associated with changes in LDL-oxidizability indices (P</=0.01). Thus, LA effectively decreased LDL pool size, inducing the presence of less buoyant lipoproteins, which were less susceptible to in vitro oxidation. This was not explained by changes in vitamin E levels, but by short-term changes in the fatty acids composition.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoproteins B / blood
  • Blood Component Removal*
  • Cholesterol / blood
  • Cholesterol Esters / blood
  • Cholesterol, LDL / blood
  • Combined Modality Therapy
  • Fatty Acids / analysis
  • Humans
  • Hypercholesterolemia / blood*
  • Hypercholesterolemia / drug therapy
  • Hypercholesterolemia / therapy
  • Hypolipidemic Agents / therapeutic use
  • Lipoproteins, LDL / chemistry
  • Lipoproteins, LDL / metabolism*
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Simvastatin / therapeutic use
  • Vitamin E / analysis

Substances

  • Apolipoproteins B
  • Cholesterol Esters
  • Cholesterol, LDL
  • Fatty Acids
  • Hypolipidemic Agents
  • Lipoproteins, LDL
  • oxidized low density lipoprotein
  • Vitamin E
  • Cholesterol
  • Simvastatin